Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
Top Page
Xspray Pharma AB
(Berlin:XSPRAY)
47Neutral
Xspray Pharma AB (XSPRAY) vs. S&P 500 (SPY)
Market Cap
€1.15B
Dividend YieldN/A
Average Volume (3M)21.99K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth-19.44%
CountrySE
Employees27
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.14
Shares Outstanding37,138,493
10 Day Avg. Volume24,906
30 Day Avg. Volume21,994
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.71
Price to Sales (P/S)0.00
P/FCF Ratio-3.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Xspray Pharma AB Business Overview & Revenue Model
Company DescriptionXspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.
How the Company Makes MoneyXspray Pharma makes money by developing and commercializing improved versions of existing cancer drugs. The company's revenue model is based on licensing agreements and collaborations with larger pharmaceutical companies that have the resources and distribution networks to market the drugs. By using its HyNap technology, Xspray creates formulations that offer competitive advantages over original drugs, such as enhanced bioavailability and reduced side effects, making them attractive for licensing. Xspray typically earns upfront payments, milestone payments, and royalties from these partnerships. Additionally, the company may also generate revenue through direct sales if it chooses to commercialize certain products independently.
Xspray Pharma AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -1.64M | -9.19M | -9.53M | -8.87M | -1.41M | -4.80M | EBIT |
| -285.71M | -180.76M | -133.07M | -97.95M | -53.46M | -45.70M | EBITDA |
| -275.20M | -169.81M | -122.13M | -87.82M | -50.99M | -40.90M | Net Income Common Stockholders |
| -285.52M | -179.67M | -130.27M | -96.70M | -52.30M | -45.84M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 192.85M | 166.30M | 120.17M | 271.88M | 325.60M | 209.87M | Total Assets |
| 307.38M | 765.26M | 585.43M | 622.90M | 605.30M | 400.67M | Total Debt |
| 8.28M | 36.81M | 2.13M | 3.23M | 4.86M | 5.33M | Net Debt |
| -184.57M | -129.50M | -118.04M | -268.65M | -320.74M | -204.54M | Total Liabilities |
| 14.16M | 71.85M | 29.41M | 31.15M | 22.72M | 26.96M | Stockholders Equity |
| 293.21M | 693.41M | 556.02M | 591.75M | 582.59M | 373.71M |
| Cash Flow | Free Cash Flow | ||||
| -264.51M | -257.38M | -238.47M | -147.57M | -145.00M | -126.23M | Operating Cash Flow |
| -222.37M | -203.28M | -110.18M | -51.61M | -47.79M | -34.24M | Investing Cash Flow |
| -42.14M | -65.88M | -135.34M | -105.82M | -96.83M | -91.99M | Financing Cash Flow |
| 306.11M | 315.59M | 93.81M | 103.71M | 260.35M | 114.84M |
Xspray Pharma AB Technical Analysis
Negative
31.00
Price Trends
31.59
Negative
33.01
Negative
40.77
Negative
Market Momentum
0.14
Positive
44.40
Neutral
28.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Negative. The current price of 31 is below the 20-day moving average (MA) of 34.32, below the 50-day MA of 31.59, and below the 200-day MA of 40.77, indicating a bearish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 28.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XSPRAY.
Xspray Pharma AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr1.14B | 5.07 | 179.17% | ― | 1887.36% | ― | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
48 Neutral | €901.76M | ― | -43.97% | ― | ― | 67.70% | |
48 Neutral | kr390.71M | ― | -47.73% | ― | 45.52% | 93.35% | |
47 Neutral | €1.15B | ― | -42.24% | ― | ― | -19.44% | |
41 Neutral | €371.90M | ― | -194.31% | ― | 1643.36% | 50.36% | |
31 Underperform | €378.88M | ― | -167.55% | ― | ― | 46.67% |
* Healthcare Sector Average
Performance Comparison
SE:XSPRAY
Xspray Pharma AB
31.00
-24.34
-43.98%
SE:CANTA
Cantargia AB
1.52
-2.25
-59.58%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.17
-8.43
-54.04%
SE:SANION
Saniona AB
8.44
6.46
327.13%
SE:XBRANE
Xbrane Biopharma AB
0.26
0.03
11.35%
SE:SYNACT
SynAct Pharma AB
18.40
11.47
165.47%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.